These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23478537)

  • 21. Biopsies for "normal" PSA? Certain relatively young, healthy men with PSA levels below 4 should consider having a biopsy.
    Gerber GS
    Health News; 2004 Jul; 10(7):4-5. PubMed ID: 15239153
    [No Abstract]   [Full Text] [Related]  

  • 22. Knowledge, attitude and practice regarding prostate specific antigen (PSA) and prostate biopsy.
    Nazim SM; Raza SJ; Ather MH
    J Coll Physicians Surg Pak; 2013 Jul; 23(7):529-30. PubMed ID: 23823969
    [No Abstract]   [Full Text] [Related]  

  • 23. [How to select the best candidates for prostate biopsies? The role of traditional tools and contribution of new biomarkers in prostate cancer].
    Audenet F; Rouprêt M; Perrin P; de La Taille A
    Prog Urol; 2011 May; 21 Suppl 3():S88-92. PubMed ID: 21616446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
    Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
    Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen 'velocity' as a diagnostic test for prostate cancer.
    Concato J; Wells CK
    J Investig Med; 2006 Nov; 54(7):361-4. PubMed ID: 17169256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pitfalls in interpreting prostate specific antigen velocity.
    Kadmon D; Weinberg AD; Williams RH; Pavlik VN; Cooper P; Migliore PJ
    J Urol; 1996 May; 155(5):1655-7. PubMed ID: 8627846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer.
    Thiel R; Pearson JD; Epstein JI; Walsh PC; Carter HB
    Urology; 1997 May; 49(5):716-20. PubMed ID: 9145976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer.
    Semjonow A; Hamm M; Rathert P; Hertle L
    Br J Urol; 1994 May; 73(5):538-43. PubMed ID: 7516808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSA Screening for Prostate Cancer.
    Quaas J
    Am Fam Physician; 2015 May; 91(9):Online. PubMed ID: 25955746
    [No Abstract]   [Full Text] [Related]  

  • 31. PSA velocity and prostate cancer.
    Dodd LE; Simon R
    N Engl J Med; 2004 Oct; 351(17):1800-2; author reply 1800-2. PubMed ID: 15496635
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial comment to association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.
    Shimbo M
    Int J Urol; 2012 Aug; 19(8):747-8. PubMed ID: 22651131
    [No Abstract]   [Full Text] [Related]  

  • 33. Prostate cancer: is PSA velocity useful?
    Loeb S
    Nat Rev Urol; 2009 Jun; 6(6):305-6. PubMed ID: 19498408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of prostate-specific antigen kinetics to stratify risk in prostate cancer.
    Presti J
    Curr Urol Rep; 2008 May; 9(3):226-30. PubMed ID: 18765117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [PSAD and PSA-AD in the early diagnosis of cancer of the prostate].
    Allepuz Losa C; Sanz JI; Carela J; Benejam J; García-Miralles R; Rioja Sanz LA
    Actas Urol Esp; 1997 Oct; 21(9):843-51. PubMed ID: 9471867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer volume adds significantly to prostate-specific antigen in the prediction of early biochemical failure after external beam radiation therapy.
    D'Amico AV; Propert KJ
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):273-9. PubMed ID: 8635933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of prostate gland volume on cryoablation prostate-specific antigen outcomes.
    Levy DA; Jones JS
    Urology; 2011 Apr; 77(4):994-8. PubMed ID: 21333336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnosis of leukemic infiltration of the prostate p6ompted by PSA elevation].
    Pérez Arbej JA; López Carreira M; Arnaiz Esteban F; Martínez Pérez E; Nogueras Gimeno MA; Espuela Orgaz R; Crespo Mayor V
    Actas Urol Esp; 1996; 20(10):892-4. PubMed ID: 9139533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial Comment to Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer.
    Yashi M
    Int J Urol; 2015 Jun; 22(6):561-2. PubMed ID: 25799888
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostate cancer: PSA velocity in prostate cancer screening--the debate continues.
    Borofsky MS; Makarov DV
    Nat Rev Urol; 2011 Jul; 8(8):413-4. PubMed ID: 21750502
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.